The US Food and Drug Administration has granted San Diego-based regenerative-medicine company Cytori Therapeutics, Inc. conditional approval for an Investigational Device Exemption or IDE for a central study dubbed, STAR. The investigation will evaluate Cytori Cell Therapy‘s efficacy as a new solution for impaired hand function in patients with…
Actelion Pharmaceuticals Ltd., has just announced its has sent the European Medicines Agency (EMA) an application for the centralized Marketing Authorization of selexipag (Uptravi®), indicated for the treatment of pulmonary arterial hypertension (PAH). While the drug’s MAA is pending validation, the company is working…
A recent study entitled “Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience,” published in the journal Lung India, compared the clinical spectrum of diffuse parenchymal lung diseases (DPLD) with idiopathic pulmonary fibrosis…
Image Courtesy of TomTec Imaging Systems TomTec Imaging Systems, a Munich-based company specializing in medical imaging and information management software with a focus on ultrasound technologies, has just announced its groundbreaking 4D RV-Function© software that allows extensive assessment of the right ventricle (RV) of the heart. This diagnostic and…
The Pulmonary Hypertension Association has just launched a Transplant E-mail Group, designed to support and educate those who are waiting for or interested in applying for a potentially life-saving lung transplant. There is still no known cure for pulmonary hypertension, which is a…
The University of California San Diego Health System, a leader in chronic thromboembolic pulmonary hypertension (CTEPH) research and patient care, has just received a generous grant to fund the recent launch of the country’s first CTEPH registry. The $7.6 million grant comes from pharmaceutical giant Bayer HealthCare in time for the November Pulmonary…
Critical care company Ikaria, Inc. and biopharmaceutical company Lee’s Pharmaceutical Holdings Limited (Lee’s Pharm) have just signed signed a new agreement to drive the registration and commercial approval of INOMAX® (nitric oxide), a breakthrough inhaled treatment of hypoxic respiratory failure (HRF), in China, Hong Kong, Macau and Taiwan. The drug will be offered as a Total Care…
Vanderbilt Heart & Vascular Institute (VHVI) is offering a novel and specialized surgical approach for treating patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension (PH) that can cause breathing difficulties, acute pulmonary embolism, or blood clots in the lung. Even though the condition…
Bayer HealthCare recently launched a contest with the goal of raising awareness about pulmonary hypertension (PH) and gathering support for PH patients and their families. Of particular focus in this contest is a type of PH called CTEPH, or chronic thromboembolic pulmonary hypertension. Breathless Moments…
November is Prematurity Awareness Month, and in light of World Prematurity Day celebrated yesterday, November 17, Nationwide Children’s Hospital shared with the pulmonary hypertension community the benefits of administering Sildenafil to premature newborn babies with pulmonary hypertension. Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor more popularly…
Photo of Roseanne Huber from http://phadailybeat.blogspot.pt The Pulmonary Hypertension Association recently reached out to running enthusiast and pulmonary hypertension patient Roseanne Huber from Florida to share her insightful story of taking control of her condition. Huber was diagnosed with the life-threatening disease in 2006…
Members of the Pulmonary Hypertension Association (PHA) accompanied PH patients from across the country yesterday to meet with Members of Congress. November is Pulmonary Hypertension Awareness Month, and to boost support for national efforts against this life threatening cardiopulmonary disease, they discussed the everyday plight…
Get regular updates to your inbox.